Research programme: aldosterone antagonists - BTG
Latest Information Update: 21 Aug 2019
At a glance
- Originator BTG
- Class
- Mechanism of Action Aldosterone antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic heart failure; Hypertension
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-heart-failure in United Kingdom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertension in United Kingdom